Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Jeff Patton, MD, CEO and board member of OneOncology and executive chairman of Tennessee Oncology, joins hosts Emeline Aviki, MB, MBA, medical director and attending surgeon at NYU Langone Perlmutter Cancer Center, and Stephen Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, for episode 3 of, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Patton, also chairman of the Community Oncology Alliance and a board-certified hematologist and oncologist, highlights of the origins of OneOncology that it was created to protect community oncology, to give other states and communities the opportunity to stay independent in light of large hospital systems, if they wanted to. He also discusses the importance of community clinical trial accrual and of keeping oncological services within the community and not handing them over to large hospital systems, thereby driving up the cost of care.
“OneOncology was created by physicians for physicians to maintain the autonomy and allow physicians the choice of seeing patients in the community vs in a hospital or academic medical center,” he emphasizes. “I think every patient, every family deserves choice. In many cases, and in most cases, we feel like the community option is the best.”
For complete interview audio:
Listen above or on one of these podcast services:
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More